Bristol-Myers Squibb Co (NYSE:BMY) has announced an exclusive agreement with BAVARIAN NORDIC (OTCMKTS:BVNRY) over the Danish-based companyandrsquo;s prostate cancer drug Prostvac, which is currently undergoing clinical trials. The deal could be worth up to almost $1 billion if the clinical trials yield positive results.
Bristol-Myers Squibb Co (BMY) Signs Exclusive Prostate-Cancer Deal With Bavarian Nordic
Bidness etc. - 4 Mar 2015 21:19
Bristol-Myers Squibb Co (NYSE:BMY) has announced an exclusive agreement with BAVARIAN NORDIC (OTCMKTS:BVNRY) over the Danish-based companyandrsquo;s prostate cancer drug Prostvac, which is currently undergoing clinical trials. The deal could be worth up to almost $1 billion if the clinical trials yield positive results.
Share this Article
Recommended